secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069254
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025
--------------------------------------------------------------------

- Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.
- Cash, cash equivalents and marketable securities totaled $328.5M as of March 31, 2025, funding operations into mid-2027.
- Full data from Group 1 of Phase 2 REGEN-007 study expected in Q2 2025 (approx. 20 patients, ~18 months follow-up).
- FDA confirmed accelerated approval pathway for rilparencel in Q4 2024; details expected mid-2025 after Type B meeting.
- R&D expenses flat at $27.3M; G&A increased to $14.4M from $12.8M in prior-year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/0000950170-25-069254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017025069254/prok-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer